[go: up one dir, main page]

PE20120496A1 - Formulacion farmaceutica de estriol de administracion vaginal - Google Patents

Formulacion farmaceutica de estriol de administracion vaginal

Info

Publication number
PE20120496A1
PE20120496A1 PE2011001250A PE2011001250A PE20120496A1 PE 20120496 A1 PE20120496 A1 PE 20120496A1 PE 2011001250 A PE2011001250 A PE 2011001250A PE 2011001250 A PE2011001250 A PE 2011001250A PE 20120496 A1 PE20120496 A1 PE 20120496A1
Authority
PE
Peru
Prior art keywords
estriol
vaginal administration
pharmaceutical formulation
pharmaceutical composition
cremigel
Prior art date
Application number
PE2011001250A
Other languages
English (en)
Inventor
Fernandez Alvaro Acebron
Lousame Dolores Blanco
Del Prado Jaime Moscoso
Magro Concepcion Nieto
Original Assignee
Italfarmaco Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Sa filed Critical Italfarmaco Sa
Publication of PE20120496A1 publication Critical patent/PE20120496A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) ESTRIOL CUYA DOSIS COMPRENDE ENTRE 0,02-0,07 mg/DIA; Y B) AL MENOS UN POLIMERO BIOADHESIVO SELECCIONADO DE POLIMEROS DE CELULOSA, GOMAS NATURALES, ALGINATO DE SODIO, POLIOXIETILENOS, POLIMEROS ACRILICOS Y SUS MEZCLAS. DICHA COMPOSICION FARMACEUTICA ES UN GEL MUCOADHESIVO, CREMIGEL O CREMA DE ADMINISTRACION VAGINAL. REFERIDA TAMBIEN AL USO DE ESTRIOL EN EL TRATAMIENTO DE ATROFIA UROGENITAL EN MUJERES CON UNA PROBABILIDAD ELEVADA DE DE PADECER UNA PATOLOGIA CARDIOVASCULAR
PE2011001250A 2008-12-19 2009-08-07 Formulacion farmaceutica de estriol de administracion vaginal PE20120496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200803623A ES2344675B1 (es) 2008-12-19 2008-12-19 Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.

Publications (1)

Publication Number Publication Date
PE20120496A1 true PE20120496A1 (es) 2012-05-04

Family

ID=41050933

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001250A PE20120496A1 (es) 2008-12-19 2009-08-07 Formulacion farmaceutica de estriol de administracion vaginal

Country Status (24)

Country Link
US (1) US8835414B2 (es)
EP (1) EP2376086B1 (es)
JP (1) JP2012512818A (es)
KR (1) KR101734380B1 (es)
CN (1) CN102325533A (es)
CA (1) CA2747314C (es)
CL (1) CL2011001493A1 (es)
CO (1) CO6382128A2 (es)
CY (1) CY1120971T1 (es)
DK (1) DK2376086T3 (es)
EC (1) ECSP11011211A (es)
ES (2) ES2344675B1 (es)
HR (1) HRP20182022T1 (es)
HU (1) HUE040394T2 (es)
LT (1) LT2376086T (es)
MA (1) MA32984B1 (es)
MX (1) MX2011006696A (es)
PE (1) PE20120496A1 (es)
PL (1) PL2376086T3 (es)
PT (1) PT2376086T (es)
RU (1) RU2555752C2 (es)
SI (1) SI2376086T1 (es)
SM (1) SMT201800648T1 (es)
WO (1) WO2010069621A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246934B2 (en) * 2015-01-05 2022-02-15 B.G. Negev Technologies & Applications Ltd. At Ben-Gurion University Nanoparticles and methods for preparation thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1866M (fr) 1961-04-07 1963-06-17 Vismara Francesco Spa Nouveaux éthers des hormones oestrogenes.
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
EP0452334A4 (en) 1989-10-31 1991-12-11 Watson Laboratoires, Inc. Mucoadhesive carrier for delivery of therapeutical agent
ES2050096T3 (es) 1989-10-31 1995-01-16 Columbia Lab Inc Composicion humidificante del tejido vaginal.
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
IT1275816B1 (it) 1995-10-27 1997-10-17 Montefarmaco Spa Composizioni farmaceutiche solide per uso vaginale
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
AP1209A (en) 1996-11-14 2003-09-30 Lipomedica Ehf Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglceride derivatives thereof for treating of mucosa infections.
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
CA2366688A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
WO2001028515A1 (en) 1999-10-22 2001-04-26 Líf-Hlaup ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
RS52149B (sr) * 2000-01-18 2012-08-31 Bayer Schering Pharma Aktiengesellschaft Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona
DE60143360D1 (de) 2000-08-03 2010-12-09 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
JP3655846B2 (ja) 2001-06-27 2005-06-02 埼玉日本電気株式会社 Ｃｄｍａ移動通信システム、及びその呼切断防止方法
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
PE20070329A1 (es) 2005-08-12 2007-03-29 Drugtech Corp Composiciones con estrogenos y metodos terapeuticos para su uso
CA2578790A1 (en) 2005-12-16 2007-06-16 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
MX2008009177A (es) * 2006-01-20 2008-12-05 Pear Tree Pharmaceuticals Inc Metodo para tratar vaginitis atrofica.
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008089405A1 (en) 2007-01-19 2008-07-24 Neurosci, Inc. Composition of multiple hormones delivered vaginally in a single cream
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.

Also Published As

Publication number Publication date
CO6382128A2 (es) 2012-02-15
WO2010069621A8 (en) 2011-07-21
MA32984B1 (fr) 2012-01-02
RU2555752C2 (ru) 2015-07-10
JP2012512818A (ja) 2012-06-07
ES2344675A1 (es) 2010-09-02
US20110312929A1 (en) 2011-12-22
SMT201800648T1 (it) 2019-01-11
CN102325533A (zh) 2012-01-18
HUE040394T2 (hu) 2019-03-28
EP2376086A1 (en) 2011-10-19
LT2376086T (lt) 2019-01-10
CA2747314A1 (en) 2010-06-24
KR20110108358A (ko) 2011-10-05
CA2747314C (en) 2017-04-18
CY1120971T1 (el) 2019-12-11
ES2344675B1 (es) 2011-04-28
ES2707873T3 (es) 2019-04-05
PT2376086T (pt) 2018-12-18
CL2011001493A1 (es) 2012-01-13
WO2010069621A1 (en) 2010-06-24
PL2376086T3 (pl) 2019-05-31
US8835414B2 (en) 2014-09-16
SI2376086T1 (sl) 2019-02-28
HRP20182022T1 (hr) 2019-01-25
ECSP11011211A (es) 2011-08-31
EP2376086B1 (en) 2018-09-19
RU2011127702A (ru) 2013-01-27
KR101734380B1 (ko) 2017-05-11
MX2011006696A (es) 2011-07-28
DK2376086T3 (en) 2018-12-10

Similar Documents

Publication Publication Date Title
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
Mittal et al. Comparative evaluation of the antibacterial and physical properties of conventional glass ionomer cement containing chlorhexidine and antibiotics
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
CY1116874T1 (el) Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος
MX2009013427A (es) Uso de estirol en bajas dosis.
AR022252A1 (es) Composicion de administracion oral.
MY153658A (en) Methods of making compositions comprising films
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
CO6400186A2 (es) Tabletas de acetato de ulipristal
CY1114499T1 (el) Βιοδιαθεσιμες στερεες δοσολογικες μορφες μεταξαλονης
CO6771406A2 (es) Una composición combinada
AR069665A1 (es) Composiciones para modelar el cabello y metodos de uso
MX2021015846A (es) Derivados de antraciclina.
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
WO2023001248A9 (zh) 一种含抗trop2抗体药物偶联物的药物组合物及其用途
GT200600307A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
CL2009001328A1 (es) Compuestos derivados de 3-oxo-isoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno del dolor.
PE20120496A1 (es) Formulacion farmaceutica de estriol de administracion vaginal
EA200702102A1 (ru) Пластинки, содержащие стероидные гормоны
ATE491341T1 (de) Essbare, sich auflösende gelatinestreifen
AR057474A1 (es) Composiciones de donepezil gelificado y metodos para la fabricacion y utilizacion de las mismas
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
AR043370A1 (es) Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga
CL2011000252A1 (es) Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.
AR118580A1 (es) Formulación de tableta vaginal

Legal Events

Date Code Title Description
FC Refusal